Divarasib Study in Untreated Advanced NSCLC Shows Promise for Safety and Efficacy
A study is underway to evaluate the safety, pharmacokinetics, and activity of divarasib in advanced or metastatic NSCLC.
Asset / Drug
Drug and asset intelligence for Divarasib with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.